Archives     Advertise     Editorial Calendar      Advertiser Index     Subscribe     Contact Us    

Forty-Three Percent of Melanoma Patients Have Chronic Complications from Immunotherapies

Douglas Johnson, MD, MSCI

Chronic side effects among melanoma survivors after treatment with anti-PD-1 immunotherapies are more common than previously recognized, according to a study published March 25 in JAMA Oncology.

The chronic complications, which occurred in 43% of patients, affected the joints and endocrine system most commonly, and less often involved salivary glands, eyes, peripheral nerves and other organs. These complications may be long lasting, with only 14% of cases having been resolved at last follow-up. This finding contrasted with previously reported immunotherapy-related acute complications that affected visceral organs -- including the liver, colon, lungs and kidneys -- which were effectively treated with steroids. However, the vast majority of chronic complications were not severe or life threatening.

"Chronic and long-lasting side effects were more common than we expected and involved a variety of often overlooked organs like the thyroid, salivary glands and joints," said the study's senior author, Douglas Johnson, MD, MSCI, associate professor of Medicine at Vanderbilt University Medical Center and clinical director of Melanoma at Vanderbilt-Ingram Cancer Center.

The retrospective study reviewed the incidence and spectrum of chronic immune-related adverse events in melanoma patients who were treated with adjuvant anti-PD-1 immunotherapies (pembrolizumab or nivolumab) at eight academic medical centers between 2015 and 2020. Chronic complications were defined as those persisting at least 12 weeks after immunotherapy treatments had ended. The study is the first to systematically examine anti-PD-1-related chronic complications in patients with high-risk, resected melanoma.

Most of the chronic complications (96%) were grade 1 or 2 events with no or mild symptoms. The more common complications included adrenal insufficiency, arthritis, dermatitis and thyroiditis.

Rare and acute immune-related adverse events that occur early in the course of treatment with the immunotherapy, such as cardiovascular complications, can be more serious. Johnson and colleagues at Vanderbilt-Ingram first reported in 2016 rare but fatal cardiac side effects from immunotherapies.

"While these side effects are important to monitor and treat, anti-PD-1 therapies remain life saving for many patients with melanoma" Johnson said.

The study's lead author is J. Randall Patrinely, Jr., BA. Other contributing authors from Vanderbilt included Fei Ye, PhD; Ran Fan, PhD and Elizabeth Davis, MD.


Related Articles:

Recent Articles

Answering the Call to Train More Physicians

Local healthcare leaders address the growing need for doctors nationwide

Read More

Back to School with COVID

After enjoying a taste of 'return to normal' earlier this year, the Delta variant has changed the trajectory of the pandemic and plunged communities into crisis again.

Read More

Addressing Kids' Health in Tennessee

New plans designed to impact social determinants of health among Tennessee's kids

Read More

ACS Updates Children's Surgery Verification Program Standards

Updated standards from ACS Children's Surgery Verification Program emphasize new patient care expectations for participating hospitals.

Read More

Q&A with New Nashville Health Care Council Fellows Director Lydie Marc

Meet the Nashville Health Care Council's new Fellows Director Lydie Marc and hear about plans for the upcoming session.

Read More

An Innovator in Joint Replacement

TriStar Centennial orthopaedist Dr. Jeff Hodrick is proving less is more when it comes to pain relief.

Read More

News of Note in Orthopaedics & Pain Management

New providers, centers and services give Middle Tennessee patients more option for pain relief and care.

Read More

An Integrative Approach to Pain Management

Patients benefit when providers work together

Read More

Medicare ACOs Increased Savings for Seventh Straight Year

Medicare's largest alternative payment model produced its highest annual savings to date in 2020, while continuing to provide high-quality care, as shown by performance data released today by the Centers for Medicare & Medicaid Services (CMS).

Read More

Supporting Value in Healthcare for All

While the move to value-based care continues to progress, healthcare groups look for more supports and fix to 'rural glitch.'

Read More

Email Print



Powered by Bondware
News Publishing Software

The browser you are using is outdated!

You may not be getting all you can out of your browsing experience
and may be open to security risks!

Consider upgrading to the latest version of your browser or choose on below: